Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Fesoterodine
Therapeutic Area : Urology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Fesoterodine Fumarate Extended-Release Tablets, a therapeutic generic equivalent to Toviaz® (fesoterodine fumarate) Extended-Release Tablets, a muscarinic antagonist indicated for the treatment of overactive bladder.
Product Name : Fesoterodine Fumarate-Generic
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 07, 2022
Lead Product(s) : Fesoterodine
Therapeutic Area : Urology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Fesoterodine
Therapeutic Area : Urology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Alembic Fesoterodine Fumarate-Generic is therapeutically equivalent to Pfizer Fesoterodine Fumarate Extended-Release Tablets indicated for the treatment of overactive bladder in adults with symptoms of urge urinary incontinence, urgency, and frequency.
Product Name : Fesoterodine Fumarate-Generic
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 02, 2022
Lead Product(s) : Fesoterodine
Therapeutic Area : Urology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable